NO934706L - Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner - Google Patents

Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner

Info

Publication number
NO934706L
NO934706L NO934706A NO934706A NO934706L NO 934706 L NO934706 L NO 934706L NO 934706 A NO934706 A NO 934706A NO 934706 A NO934706 A NO 934706A NO 934706 L NO934706 L NO 934706L
Authority
NO
Norway
Prior art keywords
phenyl
pyridones
substituted
alkoxypyridines
hyperlipoproteinemia
Prior art date
Application number
NO934706A
Other languages
English (en)
Norwegian (no)
Other versions
NO934706D0 (no
Inventor
Rolf Angerbauer
Peter Fay
Walter Hubsch
Thomas Philipps
Hilmar Bischoff
Hans-Peter Krause
Jorg Petersen-Von Gehr
Delf Schmidt
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4321421A external-priority patent/DE4321421A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO934706D0 publication Critical patent/NO934706D0/no
Publication of NO934706L publication Critical patent/NO934706L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO934706A 1992-12-21 1993-12-20 Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner NO934706L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4243278 1992-12-21
DE4321421A DE4321421A1 (de) 1992-12-21 1993-06-28 Substituierte 4-Phenyl-pyridone und 4-Phenyl-2-alkoxypyridine

Publications (2)

Publication Number Publication Date
NO934706D0 NO934706D0 (no) 1993-12-20
NO934706L true NO934706L (no) 1994-06-22

Family

ID=25921579

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934706A NO934706L (no) 1992-12-21 1993-12-20 Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner

Country Status (21)

Country Link
US (1) US5418243A (zh)
EP (1) EP0603649B1 (zh)
JP (1) JPH06234741A (zh)
CN (1) CN1117965A (zh)
AT (1) ATE140226T1 (zh)
AU (1) AU660132B2 (zh)
CA (1) CA2111778A1 (zh)
CZ (1) CZ284093A3 (zh)
DE (1) DE59303195D1 (zh)
DK (1) DK0603649T3 (zh)
ES (1) ES2089687T3 (zh)
FI (1) FI935728A (zh)
GR (1) GR3020668T3 (zh)
HU (1) HUT70150A (zh)
IL (1) IL108071A0 (zh)
MX (1) MX9308013A (zh)
NO (1) NO934706L (zh)
NZ (1) NZ250500A (zh)
PH (1) PH29953A (zh)
PL (1) PL301582A1 (zh)
SK (1) SK144893A3 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19627420A1 (de) * 1996-07-08 1998-01-15 Bayer Ag 6-(Hydroxymethyl-ethyl)pyridine
JP2005126340A (ja) * 2003-10-22 2005-05-19 Kureha Chem Ind Co Ltd 置換ピリドン類の製造法、その原料化合物及びその製造方法
AR059898A1 (es) * 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
NZ584152A (en) * 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
PT2203439E (pt) 2007-09-14 2011-02-11 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas
JP5433579B2 (ja) * 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 1,3−二置換−4−フェニル−1h−ピリジン−2−オン
MX2010005110A (es) * 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
BRPI0918055A2 (pt) 2008-09-02 2015-12-01 Addex Pharmaceuticals Sa derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
CA2738849C (en) 2008-10-16 2016-06-28 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
SI3096790T1 (sl) 2014-01-21 2019-11-29 Janssen Pharmaceutica Nv Kombinacije, ki vsebujejo pozitivne aleostrične modulatorje ali ortosterične agoniste metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
CN104370806B (zh) * 2014-06-17 2017-07-07 中国海洋大学 一种吡啶酮生物碱类化合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564502A (en) * 1975-07-31 1980-04-10 Smith Kline French Lab Guanidines thioureas and 1,1-diamino-2-nitroethylene derivatives
US4154838A (en) * 1975-07-31 1979-05-15 Smith Kline & French Laboratories Limited Alkoxy pyridine
US4684477A (en) * 1985-03-06 1987-08-04 Chisso Corporation Pyridine derivatives and their use in liquid crystals
US4906624A (en) * 1987-09-08 1990-03-06 Warner-Lambert Company 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
EP0339342A1 (de) * 1988-04-23 1989-11-02 Bayer Ag N-Substituierte N-Amino-pyrrole
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5032602A (en) * 1988-12-14 1991-07-16 Bayer Aktiengesellschaft Inhibiting HMG-CoA reductase with novel substituted 2-pyridones and pyrid-2-thiones
DE3909378A1 (de) * 1989-03-22 1990-09-27 Bayer Ag Substituierte biphenyle
DE3925636A1 (de) * 1989-08-03 1991-02-07 Bayer Ag Imino-substituierte pyridine

Also Published As

Publication number Publication date
HUT70150A (en) 1995-09-28
CA2111778A1 (en) 1994-06-22
FI935728A0 (fi) 1993-12-20
ATE140226T1 (de) 1996-07-15
SK144893A3 (en) 1995-02-08
GR3020668T3 (en) 1996-10-31
CZ284093A3 (en) 1994-07-13
JPH06234741A (ja) 1994-08-23
ES2089687T3 (es) 1996-10-01
HU9303675D0 (en) 1994-04-28
PH29953A (en) 1996-09-16
DK0603649T3 (da) 1996-11-04
EP0603649A1 (de) 1994-06-29
NZ250500A (en) 1996-02-27
AU660132B2 (en) 1995-06-08
MX9308013A (es) 1994-08-31
EP0603649B1 (de) 1996-07-10
CN1117965A (zh) 1996-03-06
FI935728A (fi) 1994-06-22
AU5195593A (en) 1994-06-30
PL301582A1 (en) 1994-06-27
IL108071A0 (en) 1994-04-12
DE59303195D1 (de) 1996-08-14
US5418243A (en) 1995-05-23
NO934706D0 (no) 1993-12-20

Similar Documents

Publication Publication Date Title
NO934706L (no) Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner
CA2083179A1 (en) Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
MX9300766A (es) Piridonas sustituidas por sulfonilbencilo, procedimiento para su obtencion y medicamentos que las contienen.
MY114889A (en) 1-phenyl-3-dimethylamino-propane derivatives having pharmacological activity
ES2124793T3 (es) Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores.
HU9302496D0 (en) Method for producing anti-viral nucleoside combinations and one for preparing medical preparatives containing said compounds
DE59710893D1 (de) Kosmetische oder pharmazeutische zubereitungen mit vermindertem klebrigkeitsgefühl
AU2740797A (en) Androstene derivatives
NO954878L (no) Pyrrolderivater
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
NO952781L (no) Potensiering av temozolomid i humane tumorceller
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
AU2861389A (en) Disubstituted pyridines
ATE261737T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
DE59107336D1 (de) Oligosaccharidderivate und deren Verwendung in Heilmitteln
NO20001758L (no) FremgangsmÕter og blandinger for behandling av leddgikt
WO1993005807A3 (en) Erythropoietin potentiating agents and methods for their use
CA2003213A1 (en) Antimycotically active cyclopropyl-substituted azolylmethylcarbinols
GR3017967T3 (en) Substituted pyrido-oxazines.
DE69230644D1 (de) Verwendung von protease nexin-i als mittel gegen entzündungen
FI961339A0 (fi) Triaryylieteenijohdannaiset käytettäväksi hoidossa
NO980175L (no) Anvendelse av kationiske biopolymerer for å fremstille antiflassmidler
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff